RxDoctor Payments Data

Katrina Cremeans

Family · Huntington, WVNPI 1578282745

Payments from drug & device makers

$2,312in general payments, 2019–2025

Across 96 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$345
  • Sumitomo Pharma America, Inc.$271
  • Johnson & Johnson$223
  • Pfizer$201
  • Endo USA, Inc.$176
  • Medtronic$141
  • plus $954 from 19 others

What the payments were for

  • Food & beverage$2,23096%
  • Education$824%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,312 in reported general payments places this provider in the 80th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$47,531
Medicare patients
494
Services billed
779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron34$28,066
GemtesaVibegron32$25,863
Tamsulosin Hcl561$7,561
Fesoterodine Fumarate ErFesoterodine Fumarate38$3,013
Finasteride192$2,202
Solifenacin Succinate55$1,333
Oxybutynin Chloride ErOxybutynin Chloride61$1,057
Estradiol13$922
Cephalexin76$605
Alfuzosin Hcl ErAlfuzosin Hcl21$434
Doxazosin Mesylate14$404
Doxycycline Monohydrate26$385
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$337
Cefdinir26$278
Terazosin Hcl13$253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$80$28,06634 claims
Sumitomo Pharma America, Inc.Gemtesa$271$25,86332 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,507 family providers in West Virginia.

Other family in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →